Lublin FD - Search Results

1

Early complement genes are associated with visual system degeneration in multiple sclerosis.

Fitzgerald KC, Kim K, Smith MD, Aston SA, Fioravante N, Rothman AM, Krieger S, Cofield SS, Kimbrough DJ, Bhargava P, Saidha S, Whartenby KA, Green AJ, Mowry EM, Cutter GR, Lublin FD, Baranzini SE, De Jager PL, Calabresi PA. Fitzgerald KC, et al. Among authors: lublin fd. Brain. 2019 Sep 1;142(9):2722-2736. doi: 10.1093/brain/awz188. Brain. 2019. PMID: 31289819 Free PMC article.

2

Clinical outcomes assessment in multiple sclerosis.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Rudick R, et al. Ann Neurol. 1996 Sep;40(3):469-79. doi: 10.1002/ana.410400321. Ann Neurol. 1996. PMID: 8797541 Review.

3

A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis.

Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, Doscher CA, Lublin FD, Knobler RL, Trantas F, Kelley L, Smith CR, La Rocca N, Lopez S. Miller AE, et al. Among authors: lublin fd. Neurology. 1997 Feb;48(2):312-4. doi: 10.1212/wnl.48.2.312. Neurology. 1997. PMID: 9040712 Clinical Trial.

4

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Rudick R, et al. Ann Neurol. 1997 Sep;42(3):379-82. doi: 10.1002/ana.410420318. Ann Neurol. 1997. PMID: 9307263

5

Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. Cutter GR, et al. Brain. 1999 May;122 ( Pt 5):871-82. doi: 10.1093/brain/122.5.871. Brain. 1999. PMID: 10355672

6

Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS.

Lublin FD, Reingold SC. Lublin FD, et al. Ann Neurol. 2001 May;49(5):677-81. Ann Neurol. 2001. PMID: 11357961

7

Effect of relapses on development of residual deficit in multiple sclerosis.

Lublin FD, Baier M, Cutter G. Lublin FD, et al. Neurology. 2003 Dec 9;61(11):1528-32. doi: 10.1212/01.wnl.0000096175.39831.21. Neurology. 2003. PMID: 14663037

8

The MS Co-Operative REsearch (MS-CORE) group: an alternate approach to fostering multicenter studies.

Cohen J, Cutter G, Lublin F, Schwid S. Cohen J, et al. Mult Scler. 2004 Jun;10(3):332-3. doi: 10.1191/1352458504ms1018xx. Mult Scler. 2004. PMID: 15222702 No abstract available.

9

Clinical characteristics of progressive relapsing multiple sclerosis.

Tullman MJ, Oshinsky RJ, Lublin FD, Cutter GR. Tullman MJ, et al. Among authors: lublin fd. Mult Scler. 2004 Aug;10(4):451-4. doi: 10.1191/1352458504ms1059oa. Mult Scler. 2004. PMID: 15327045

10

Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.

Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M. Frohman EM, et al. Arch Neurol. 2006 Apr;63(4):614-9. doi: 10.1001/archneur.63.4.614. Arch Neurol. 2006. PMID: 16606781 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

288 results

Search Page